A Guide Profiling 50 Canadian Venture Capital Funds

We're in! And we are VERY PROUD to be part of the class of 2026.

The CVCA's “The 50” has profiled Relentless Venture Fund in their 2026 edition.

A favorite piece of data we included as an emerging manager: our early-stage life sciences health tech fund has directly attracted over $3 billion in strategic capital through industry partnerships and investments. And no, that is neither a typo nor reflective of extended reach. That's what happens when you invest in innovators developing technology based solutions that the world needs, and in some cases, long before everyone realizes the need (and opportunity) is there. Borrowing from the Great One, we invest in where the puck is going, not in where it has been. We are a-ok with the discomfort of being early as it is often the signal you're onto something others aren't ready to see yet.

Our thesis? Pretty straightforward. The world is aging. Chronic disease is surging. And we're laser-focused on the conditions that matter most: brain health, diabetes, cardiovascular disease, respiratory disease, and mobility. The generational opportunity isn't coming. It's here.

The Relentless portfolio is built to extend a healthy lifespan, enhance independence, and improve quality of life for people living with chronic conditions. Ideally, we prevent the health issues in the first place. We invest there as well.

Thank you Canadian Venture Capital & Private Equity Association (CVCA) for the spotlight and to the Government of Canada's Trade Commissioner Service for backing this initiative.

Team Relentless doesn't do ordinary. Never have. Early stage life sciences health tech is where we live and breathe.

Link to the complete publication here: https://lnkd.in/gnqtnJFX